Literature DB >> 19382924

Cytopathological and histopathological diagnosis of canine splenic disorders.

Ni Christensen, Pj Canfield, Pa Martin, Mb Krockenberger, Ds Spielman, Kl Bosward.   

Abstract

OBJECTIVES: To determine (1) the common types of canine splenic disorders, and the breeds affected, that are diagnosed by cytopathological and histopathological examination in Sydney, Australia and (2) the accuracy of cytopathological examination compared with histopathological examination for the diagnosis of canine splenic disorders.
DESIGN: 69 cytopathological and 51 histopathological diagnoses of canine splenic disorders presented to the Veterinary Pathology Diagnostic Services, The University of Sydney during 2006 and 2007 were tabulated and analysed; 17 cases examined both cytopathologically and histopathologically during 2001-07 were also analysed.
RESULTS: The most common cytopathological diagnoses were benign disorders of growth, vascular disturbances and necrosis (29%), followed by no abnormalities detectable (28%), malignant neoplasms (20%), equivocal diagnoses (20%) and inflammatory disorders (3%). The most common breeds were Kelpie crosses and mixed breeds. The most common histopathological diagnoses were benign disorders of growth, vascular disturbances and necrosis (49%), followed by malignant neoplasms (43%) and inflammatory disorders (8%). The most common breeds were German Shepherd Dogs, Boxers and Maltese Terriers. Cytopathological and histopathological diagnoses were in complete agreement in 59% of cases, partial agreement in 29% and disagreement in 12%.
CONCLUSION: Benign disorders of growth, vascular disturbances and necrosis were the most commonly diagnosed canine splenic disorders, both cytopathologically and histopathologically. Kelpie crosses presented most frequently for cytopathological examination. German Shepherd Dogs were the most common breed diagnosed histopathologically with haemangiosarcoma. Although cytopathological and histopathological splenic examinations are complementary for diagnosis, this study has shown a high correlation for complete and partial agreement between the two.

Entities:  

Mesh:

Year:  2009        PMID: 19382924     DOI: 10.1111/j.1751-0813.2009.00421.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  6 in total

1.  Sudden death due to acute hemoabdomen and hypovolemia from a ruptured splenic hemangiosarcoma in a German shepherd dog.

Authors:  Brittany Lang
Journal:  Can Vet J       Date:  2020-11       Impact factor: 1.008

2.  Evaluation of cytological diagnostic accuracy for canine splenic neoplasms: An investigation in 78 cases using STARD guidelines.

Authors:  Marco Tecilla; Matteo Gambini; Annalisa Forlani; Mario Caniatti; Gabriele Ghisleni; Paola Roccabianca
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

3.  Clinical relevance of splenic nodules or heterogeneous splenic parenchyma assessed by cytologic evaluation of fine-needle samples in 125 dogs (2011-2015).

Authors:  Igor Yankin; Sarah Nemanic; Silvia Funes; Helio de Morais; Elena Gorman; Craig Ruaux
Journal:  J Vet Intern Med       Date:  2019-11-06       Impact factor: 3.333

Review 4.  Applications of Contrast-Enhanced Ultrasound in Splenic Studies of Dogs and Cats.

Authors:  Rute Canejo-Teixeira; Ana Lima; Ana Santana
Journal:  Animals (Basel)       Date:  2022-08-17       Impact factor: 3.231

5.  Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.

Authors:  Matthew Dowling; Jonathan Samuelson; Bahaa Fadl-Alla; Holly C Pondenis; Mark Byrum; Anne M Barger; Timothy M Fan
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

6.  Prevalence and diagnostic value of the ultrasonographic honeycomb appearance of the spleen in cats.

Authors:  Mathieu Harel; Chloe Touzet; Anthony Barthélemy; Emilie M Ségard-Weisse
Journal:  J Feline Med Surg       Date:  2019-03-21       Impact factor: 2.015

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.